Hainan Honz Pharmaceutical Co (300086) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Hainan Honz Pharmaceutical Co stock ¥0.65, price ¥4.83, that is 86.5% below the price, quality 41 out of 100. Rating: strongly overvalued. Calculated from audited financials with 7 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
60‑month range ¥3.40 – ¥13.71 · fair‑value band ¥0.4500 – ¥0.9900 · the ¥4.83 price screens above the ¥0.6500 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.
Follow Hainan Honz Pharmaceutical Co in your weekly email
Every Wednesday you see whether Hainan Honz Pharmaceutical Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Honz Pharmaceutical Co., Ltd. engages in the research and development, manufacturing, and sales of pediatric medicines in China.
Show moreShow less
The company offers medicines for children and adults in the areas of anti-anaphylaxis, antidiarrheal and digestive, relieving cough, anti-flu, antipyretic, anti-infection, anti-fungal, antipyretic-analgesic, and endocrine; and medical, disposable, and protective face masks.
It markets its products through a network of agents and sales terminals. Honz Pharmaceutical Co., Ltd. was formerly known as HaiNan Honz Pharmaceutical Co.,Ltd. and changed its name to Honz Pharmaceutical Co., Ltd. in November 2016.
Honz Pharmaceutical Co., Ltd. was founded in 1993 and is based in Guangzhou, China.
Stock analysis
Hainan Honz Pharmaceutical Co (300086) currently trades at ¥4.83, while our model-based Fair Value estimate is ¥0.6500, 87% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of ¥1.17 per share, and 0 of the 7 models we run sit above the ¥4.83 price.
Bear case: the Multiples group reads lowest at ¥0.2000, and 7 of the 7 models stay below the price. Data coverage for this calculation is low.
Scenario range: ¥0.4500 (bear) to ¥0.9900 (bull), the price of ¥4.83 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Hainan Honz Pharmaceutical Co reported revenue of 466M CNY in FY2025 versus 837M CNY in FY2021, a compound −13.6%/yr. Reported net income was −230M CNY in FY2025.
Key figures
Market cap 2.2B CNY (≈ $330M) Small · P/S ratio 6.66 · EPS (TTM) ¥−0.4600 · Dividend yield 0.7% · Net margin −62.4% · Return on equity −22.2% · Return on assets (EBIT) −5.5% (5-year average) · Operating margin −53.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).
What moves the price
The share trades about 65% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −87%, 300086 screens richer than that median.
Fair Value models
Bear¥0.4500Fair Value ¥0.6500Bull¥0.9900
Price ¥4.83 · Downside -86.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.12/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−1.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−12.7%
Start year 2020 (pandemic). Over 10 years: +1.3% a year
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
6.3% (2020) → −34.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+39.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +37.3% a year for the price.
Compare Hainan Honz Pharmaceutical Co with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 0/11 measures
Overall it trails its industry peers.
Valuation
Quality Score41 · Bottom 25%
Fair Value upside−86.5% · Bottom 25%
Profitability
Return on assets−12.9% · Bottom 25%
Net margin (12 months)−62.4% · Bottom 25%
Operating margin (12 months)−53.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−45.7% · Bottom 25%
Dividend yield (12 months)0.7% · Below median
Balance sheet
Debt / equity0.20× · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Hainan Honz Pharmaceutical Co Fair Value". https://www.fairvalue-calculator.com/stock/300086
Frequently asked questions
Is Hainan Honz Pharmaceutical Co (300086) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of ¥0.6500 versus a price of ¥4.83, about 87% lower (overvalued).
What is the fair value of 300086?
Our model-based fair value for Hainan Honz Pharmaceutical Co is ¥0.6500 (as of Nov 5, 2026), built from audited fundamentals. The current price: ¥4.83.
What is the quality score of 300086?
Hainan Honz Pharmaceutical Co has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hainan Honz Pharmaceutical Co (300086)?
Our model-based price target is the fair value of ¥0.6500 (as of Nov 5, 2026) from 7 valuation models. Cautious scenario ¥0.4500, optimistic scenario ¥0.9900. It is a calculation from audited fundamentals, not an analyst target.
What is the Hainan Honz Pharmaceutical Co stock forecast for 2026?
Our models put fair value at ¥0.6500, about 87% lower versus a price of ¥4.83 (overvalued). Cautious scenario ¥0.4500, optimistic scenario ¥0.9900. The calculation is refreshed regularly with new filings.
What is the revenue of Hainan Honz Pharmaceutical Co (300086)?
Hainan Honz Pharmaceutical Co reported trailing-twelve-month revenue of about 336M CNY (latest available figure, as of Nov 5, 2026).
Does Hainan Honz Pharmaceutical Co pay a dividend?
Hainan Honz Pharmaceutical Co currently shows a dividend yield of 0.74% relative to its recent price (as of Nov 5, 2026).
How much is the dividend of Hainan Honz Pharmaceutical Co (300086)?
Hainan Honz Pharmaceutical Co has a dividend yield of 0.7%.
What growth is priced into Hainan Honz Pharmaceutical Co (300086)?
For today's price to be fair in a discounted-cash-flow model, Hainan Honz Pharmaceutical Co would have to grow free cash flow by +39.6 % per year for five years (discount rate 10.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -12.8 % per year. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of 300086 use?
Our models discount Hainan Honz Pharmaceutical Co at 10.4 %: a base by market capitalisation (small), damped by beta 0.29, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Hainan Honz Pharmaceutical Co that is +39.6 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.4 %) and the same formula as our fair value.
How much growth has Hainan Honz Pharmaceutical Co (300086) delivered so far?
Over the past 5 years revenue at Hainan Honz Pharmaceutical Co grew -12.8 % a year. The price currently implies free-cash-flow growth of +39.6 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Hainan Honz Pharmaceutical Co (300086) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Hainan Honz Pharmaceutical Co (+39.6 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Hainan Honz Pharmaceutical Co (300086)?
The free-cash-flow yield on the price is 1.32 %: that much free cash flow Hainan Honz Pharmaceutical Co produces per unit of market value. When it exceeds the discount rate of our models (10.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Hainan Honz Pharmaceutical Co (300086)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hainan Honz Pharmaceutical Co it is ¥0.6500 per share (as of Nov 5, 2026), against a price of ¥4.83. It is the blended result of 7 valuation models in 4 families (DCF Models, Multiples, Asset-Based, Growth DCF).
Is Hainan Honz Pharmaceutical Co stock overvalued or undervalued in 2026?
As of Nov 5, 2026, 300086 trades above its calculated fair value: price ¥4.83, fair value ¥0.6500, a gap of about −87% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300086?
No. The price is what the market pays today (¥4.83); the fair value is what the company's own numbers justify (¥0.6500). For Hainan Honz Pharmaceutical Co the two are ¥4.18 per share apart. That gap is exactly why we show both numbers side by side.
How much is Hainan Honz Pharmaceutical Co worth?
The market values Hainan Honz Pharmaceutical Co at about 2.2B CNY (market capitalisation, as of Nov 5, 2026). Per share that is ¥4.83; our models calculate a fair value of ¥0.6500 per share.
What do the bullish and bearish scenarios say about 300086?
Our models span a range for Hainan Honz Pharmaceutical Co: cautious scenario ¥0.4500, base ¥0.6500, optimistic ¥0.9900 per share (as of Nov 5, 2026, price ¥4.83). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Hainan Honz Pharmaceutical Co (300086)?
Balance-sheet figures for Hainan Honz Pharmaceutical Co (as of Nov 5, 2026): return on equity −22.2%, debt of 0.20 per unit of equity. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is 300086 from its 52-week high?
Hainan Honz Pharmaceutical Co trades at ¥4.83, about 65% below its 52-week high of ¥13.71 and 5% above the low of ¥4.62 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥0.6500 is for.
Which stocks are comparable to Hainan Honz Pharmaceutical Co?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hainan Honz Pharmaceutical Co stock attractive at the current price?
The data as of Nov 5, 2026: price ¥4.83, calculated fair value ¥0.6500 (−87%), Quality Score 41/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 300086 calculated?
We run Hainan Honz Pharmaceutical Co through 7 models from 4 families: DCF Models, Multiples, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of ¥0.6500 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Hainan Honz Pharmaceutical Co itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hainan Honz Pharmaceutical Co (300086)?
The closing price on Nov 6, 2026 was ¥4.83. Our model-based fair value is ¥0.6500, about 87% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hainan Honz Pharmaceutical Co right now?
The price sits above even our optimistic bull case (¥0.9900). The favourable scenario is already priced in. Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (¥0.4500 to ¥0.9900) leaves room in how you read the outcome.
Key figures of Hainan Honz Pharmaceutical Co
How large is the market capitalisation of Hainan Honz Pharmaceutical Co (300086)?
The market capitalisation of Hainan Honz Pharmaceutical Co is 2.2B CNY (≈ $330M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hainan Honz Pharmaceutical Co (300086)?
The price-to-sales ratio of Hainan Honz Pharmaceutical Co is 6.66 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Hainan Honz Pharmaceutical Co (300086)?
Earnings per share at Hainan Honz Pharmaceutical Co are ¥−0.4600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Hainan Honz Pharmaceutical Co (300086)?
The dividend yield of Hainan Honz Pharmaceutical Co is 0.7%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Hainan Honz Pharmaceutical Co (300086)?
The net margin of Hainan Honz Pharmaceutical Co is −62.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hainan Honz Pharmaceutical Co (300086)?
The return on equity (ROE) of Hainan Honz Pharmaceutical Co is −22.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hainan Honz Pharmaceutical Co (300086)?
On an EBIT basis the return on assets of Hainan Honz Pharmaceutical Co is −5.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hainan Honz Pharmaceutical Co (300086)?
The operating margin of Hainan Honz Pharmaceutical Co is −53.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hainan Honz Pharmaceutical Co (300086)?
Revenue at Hainan Honz Pharmaceutical Co is growing −45.7% versus a year earlier (3y avg −4.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does Hainan Honz Pharmaceutical Co (300086) carry?
The net debt of Hainan Honz Pharmaceutical Co is 288M CNY (fiscal year 2025, ≈ 9.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Hainan Honz Pharmaceutical Co in the live analysis
One click puts Hainan Honz Pharmaceutical Co on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 5, 2026